Despite its part in developing a successful antibody treatment against Ebola, Canada is one of two countries that have seemingly misunderstood the science of the global outbreak and introduced a travel ban.
The Canadian government has announced it is to invest a further $23.5 million in R&D on Ebola countermeasures, such as the VSV-EBOV vaccine and ZMAPP antibody treatment developed by the Public Health Agency of Canada. The money will be used to support clinical trials of the drugs in Africa, and to assist in producing more doses of ZMAPP.
“My number one priority as minister of health is ensuring the health and safety of Canadians,” said health minister Rona Ambrose. “Today we are taking further actions to improve our preparedness for the event of a first case in Canada, and continuing to invest in R&D of vaccines and treatments that will assist in the global outbreak response.”
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.